Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1227/01.neu.0000460594.93803.cb | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Repositioning anthelmintics for the treatment of inflammatory-based pathological conditions.
Inflammopharmacology
November 2024
Laboratory of Experimental Cancerology (LabCancer), Department of Biophysics and Physiology, Center for Health Sciences, Federal University of Piauí (UFPI), Universitaria Avenue, Teresina, Piauí, 64049-550, Brazil.
Acute, uncontrolled and/or long-lasting inflammation causes a breakdown in immunological tolerance, leading to chronicity and contributing to a series of significant local or systemic tissue changes. Anti-inflammatory efficacy, fewer adverse effects, improved selectivity, and curative action are imminent issues for patients suffering from chronic inflammation-related pathologies. Then, we performed a complete and critical review about anthelmintics, discussing the main classes and the available preclinical evidence on repurposing to treat inflammation-based conditions.
View Article and Find Full Text PDFRepurposing flubendazole for glioblastoma ferroptosis by affecting xCT and TFRC proteins.
J Cell Mol Med
November 2024
Department of Neurosurgery, The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China.
New uses of old drugs hold great promise for clinical translation. Flubendazole, an FDA-approved antiparasitic drug, has been shown to target p53 and promote apoptosis in glioblastoma (GBM) cells. However, its damaging mechanism in GBM remains elusive.
View Article and Find Full Text PDFevaluation of lipidic nanocarriers for mebendazole delivery to improve anticancer activity.
Drug Dev Ind Pharm
November 2024
Pharmacological and Diagnostic Research Center, Faculty of Pharmacy, Al-Ahliyya Amman University, Amman, Jordan.
Objective: To enhance the anticancer activity of the repurposed drug mebendazole (MBZ) against A549 cell lines by developing nanostructured lipid carriers (NLCs).
Significance: MBZ, an anthelmintic drug, exhibits anticancer properties primarily through the inhibition of Ran GTPase and mitotic spindle assembly. Enhancing its delivery and efficacy via NLC could provide a novel and effective approach for lung cancer treatment.
From Deworming to Cancer Therapy: Benzimidazoles in Hematological Malignancies.
Cancers (Basel)
October 2024
Penn State Cancer Institute, Pennsylvania State University College of Medicine, Hershey, PA 17033, USA.
Drug repurposing is a strategy to discover new therapeutic uses for existing drugs, which have well-established toxicity profiles and are often more affordable. This approach has gained significant attention in recent years due to the high costs and low success rates associated with traditional drug development. Drug repositioning offers a more time- and cost-effective path for identifying new treatments.
View Article and Find Full Text PDFOral Fenbendazole for Cancer Therapy in Humans and Animals.
Anticancer Res
September 2024
Nimni-Cordoba Tissue Engineering and Drug Discovery Lab, Department of Surgery, Keck School of Medicine of University of Southern California, Los Angeles, CA, U.S.A.
Fenbendazole is a benzimidazole anthelmintic agent commonly used to treat animal parasitic infections. In humans, other benzimidazoles, such as mebendazole and albendazole, are used as antiparasitic agents. Since fenbendazole is not currently approved by the FDA or EMA, its pharmacokinetics and safety in humans have yet to be well-documented in medical literature.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!